Table SI. Baseline safety data for Case 2 before the start of nivolumab treatment.

| Variable                  | Value  |
|---------------------------|--------|
| WBC, x10^3/µl             | 10.65  |
| Neutrophil, %             | 85.7   |
| Lymphocyte, %             | 6.8    |
| Monocyte, %               | 5.6    |
| Eosinophil, %             | 1.7    |
| Basophil, %               | 0.2    |
| RBC, x10^4/µl             | 3.58   |
| Hemoglobin, g/dl          | 10.3   |
| Hematocrit, %             | 32.2   |
| Blood platelets, x10^4/µl | 399    |
| AST, U/l                  | 7      |
| ALT, U/l                  | 6      |
| LDH, U/l                  | 238    |
| ALP, U/l                  | 266    |
| γ-GT, U/l                 | 33     |
| Total protein, g/dl       | 6.9    |
| Albumin, g/dl             | 3.2    |
| Total bilirubin, mg/dl    | 0.3    |
| Creatinine, mg/dl         | 0.75   |
| eGFR, ml/min/1.73^2       | 79.5   |
| BUN, mg/dl                | 12     |
| Test                          | Value   |
|-------------------------------|---------|
| Creatine kinase, U/l          | 36      |
| Na, mmol/l                    | 137     |
| K, mmol/l                     | 4.8     |
| Cl, mmol/l                    | 101     |
| Ca, mg/dl                     | 8.4     |
| CRP, mg/dl                    | 5.9     |
| Plasma glucose, mg/dl         | 130     |
| Rheumatoid factor, U/ml       | <8.0    |
| IgG, mg/dl                    | 876     |
| IgA, mg/dl                    | 175     |
| IgM, mg/dl                    | 57      |
| KL-6, U/ml                    | 133     |
| TSH, U/ml                     | 2.63    |
| Free T4, ng/dl                | 1.18    |
| Free T3, pg/ml                | 2.28    |
| ANA, n                        | 40      |
| Homogeneous, n                | 40      |
| Speckled, n                   | 40      |
| Nucleolar, n                  | N.D.    |
| Peripheral, n                 | N.D.    |
| Discrete speckled, n          | N.D.    |
| Cytoplasmic, n                | N.D.    |
| Others, n                     | N.D.    |
|                          |        |
|--------------------------|--------|
| Urine creatinine, mg/dl  | 80     |
| Urine UN, mg/dl          | 423    |
| Urine glucose, mg/dl     | <10    |
| Urine protein, mg/dl     | 13     |
| Urine NAG, U/l           | 37.1   |

WBC, white blood cells; RBC, red blood cells; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; γ-GT, γ-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen; CRP, C-reactive protein; KL-6, sialylated carbohydrate antigen KL-6; TSH, thyroid stimulating hormone; ANA, antinuclear antibody; NAG, N-acetyl-β-D-glucosaminidase; N.D., not detected.
Table SII. Baseline safety data for Case 3 before the start of the nivolumab treatment.

| Variable               | Value  |
|------------------------|--------|
| WBC, x10³/µl           | 5.46   |
| Neutrophil, %          | 74.7   |
| Lymphocyte, %          | 9.9    |
| Monocyte, %            | 12.5   |
| Eosinophil, %          | 2.7    |
| Basophil, %            | 0.2    |
| RBC, x10⁴/µl           | 2.44   |
| Hemoglobin, g/dl       | 7.8    |
| Hematocrit, %          | 23.3   |
| Blood platelets, x10⁴/µl| 128    |
| AST, U/l               | 21     |
| ALT, U/l               | 14     |
| LDH, U/l               | 150    |
| ALP, U/l               | 51     |
| γ-GT, U/l              | 26     |
| Total protein, g/dl    | 5.4    |
| Albumin, g/dl          | 1.9    |
| Total bilirubin, mg/dl | 0.3    |
| Creatinine, mg/dl      | 0.50   |
| eGFR, ml/min/1.73²     | 116.5  |
| BUN, mg/dl             | 10     |
| Test                  | Result     |
|----------------------|------------|
| Creatine kinase, U/l | 15         |
| Na, mmol/l           | 139        |
| K, mmol/l            | 4.4        |
| Cl, mmol/l           | 102        |
| Ca, mg/dl            | 7.8        |
| CRP, mg/dl           | 11.0       |
| Plasma glucose, mg/dl| 94         |
| Rheumatoid factor, U/ml | 13.6    |
| IgG, mg/dl           | 1119       |
| IgA, mg/dl           | 336        |
| IgM, mg/dl           | 34         |
| KL-6, U/ml           | 181        |
| TSH, U/ml            | 2.38       |
| Free T4, ng/dl       | 0.918      |
| Free T3, pg/ml       | 1.14       |
| HBsAg, U/ml          | <0.005     |
| HBsAg test result    | Negative   |
| HBsAb, U/ml          | 90.5       |
| HBsAb test result    | Positive   |
| HBeAb, C.O.I         | 7.5        |
| HBeAb test result    | Positive   |
| HBV-DNA, log U/ml    | <1.0       |
| HCVAb, C.O.I         | <1.0       |
| HCV Ab test result          | Negative |
|-----------------------------|----------|
| HCV-RNA, log U/ml           | <1.2     |
| EBV-VCA Ab (IgG), n         | 160      |
| EBV-VCA Ab (IgM), n         | <10      |
| CMV antigen test result (C10/C11) | Negative |
| C10 positive cells          | 0        |
| C11 positive cells          | 0        |
| ANA, n                      | 40       |
| Homogeneous, n              | 40       |
| Speckled, n                 | N.D.     |
| Nucleolar, n                | N.D.     |
| Peripheral, n               | N.D.     |
| Discrete speckled, n        | N.D.     |
| Cytoplasmic, n              | N.D.     |
| Others, n                   | N.D.     |

WBC, white blood cells; RBC, red blood cells; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; γ-GT, γ-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen; CRP, C-reactive protein; KL-6, sialylated carbohydrate antigen KL-6; TSH, thyroid stimulating hormone; HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; HBV, hepatitis B virus; HCVAb, hepatitis C virus antibody; C.O.I., cut off index; N.D., not detected; EBV-VCA Ab, Epstein-Barr virus-viral capsid antigen antibody; CMV, cytomegalovirus; C10, cytomegalovirus low matrix phosphoprotein 65 antibody C10; C11, cytomegalovirus low matrix phosphoprotein 65 antibody C11; ANA, antinuclear antibody.